TG: తెలంగాణకు మరో భారీ పెట్టుబడి
TG: తెలంగాణ రాష్ట్రానికి మరోసారి భారీ పెట్టుబడి లభించింది. ప్రపంచ ప్రఖ్యాత ఫార్మా దిగ్గజం ‘ఎలీ లిల్లీ అండ్ కంపెనీ (Eli Lilly and Company)’
Celltrion acquires Eli Lilly's US biopharma plant for $340 million, with JP Morgan and Deutsche Bank as exclusive advisors, highlighting global IBs' growing role in cross-border M&A amid shifting supply chains.
#YonhapInfomax #Celltrion #EliLilly #JPMorgan #DeutscheBank #CrossBorderMA #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=83663
Celltrion Secures Eli Lilly Plant in US—Deutsche Bank and JP Morgan Serve as Exclusive Advisors
Celltrion acquires Eli Lilly's US biopharma plant for $340 million, with JP Morgan and Deutsche Bank as exclusive advisors, highlighting global IBs' growing role in cross-border M&A amid shifting supply chains.
Eli Lilly announces weight-loss drug to be manufactured at $6.5 billion site in Houston
The multibillion-dollar investment will result in more than 600 permanent jobs, according to the company. The manufacturing hub is slated to be built at Generation Park near Lake Houston and will produce a new weight-loss drug.
Celltrion will acquire Eli Lilly’s New Jersey biopharmaceutical plant for 460 billion won ($335 million), investing at least 1.4 trillion won ($1.02 billion) to expand US production capacity and fully eliminate tariff risks, with operations set to begin in 2027 pending regulatory approval.
#YonhapInfomax #Celltrion #EliLilly #BiopharmaceuticalPlant #TariffRisk #InvestmentAmount #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=82977
Celltrion Acquires Eli Lilly’s US Plant for 460 Billion Won—“Fully Eliminates Tariff Risk”
Celltrion will acquire Eli Lilly’s New Jersey biopharmaceutical plant for 460 billion won ($335 million), investing at least 1.4 trillion won ($1.02 billion) to expand US production capacity and fully eliminate tariff risks, with operations set to begin in 2027 pending regulatory approval.
Eli Lilly to Invest $5 Billion in Virginia Plant Amid Trump Tariff Threats
Eli Lilly will invest $5 billion in a new Virginia plant, expanding U.S. manufacturing in response to Trump's proposed pharmaceutical import tariffs.
Novo Nordisk, Maker of Wegovy, to Cut 9,000 Jobs Amid Weak Earnings
Novo Nordisk will cut 9,000 jobs globally, about 11.5% of its workforce, as weak earnings and restructuring prompt a downward revision of its profit outlook.
Chinese companies are racing to make generic versions of popular branded weight-loss drugs after regulators restricted sale of cheap copies, slowing demand for raw ingredients the firms supplied over the past two years.
https://www.japantimes.co.jp/business/2025/09/03/companies/chinese-companies-generics-us-weight/?utm_medium=Social&utm_source=mastodon #business #companies #china #pharmaceuticals #wegovy #elililly #novonordisk #fda
Chinese companies turn to generics as patents expire on weight-loss drugs
U.S. regulators have restricted the sale of cheap copies of the drugs, slowing demand for raw ingredients Chinese firms supplied over the past two years.
Eli Lilly's orforglipron just hit a game-changing milestone for obesity and Type 2 diabetes treatment, reports Annika Kim Constantino. This oral pill led to over 10% weight loss and improved blood sugar in a major trial, with easier use than injectables. Could this broaden access for patients wary of injections? Discover more:
https://www.cnbc.com/2025/08/26/eli-lilly-weight-loss-pill-orforglipron-clears-trial-paving-way-for-approval.html Great insights by Annika Kim Constantino.
#EliLilly #orforglipron #weightloss #diabetes #clinicaltrials #GLP1 #drugapproval #pharmaceuticals #obesity #healthinnovation
Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly now has the clinical trial data required to start filing for approvals of the drug for chronic weight management with global regulators.
Eli Lilly Stock Surges in Premarket: What Investors Need to Know
Eli Lilly Stock jumps in premarket after strong pill data, with clear approval steps and key risks to watch.
VaarthaRavi
EL PAÍS: el periódico global
Yonhap Infomax News
Houston Public Media
The Japan Times
WYM Mod
solister